Description

MG-132, also known as Z-Leu-leu-leu-al, is a potent, cell-permeable, reversible, and selective 26S proteasome inhibitor and calpain inhibitor. The inhibitor is used to interfere with degradation of intracellular proteins involved in inflammatory processes and cell cycle regulation. The proteasome inhibitor reduces the degradation of IkBa, and thus it inhibits TNF-a induced NF-kB activation.

MG-132 has anticancer properties. It activates c-Jun N-terminal kinase (JNK1), initiating apoptosis. It also affects various human cancer cell lines irrespective of their p53 status and is more effective in combination with drugs such as doxorubicin and etoposide.

This inhibitor induces neurite outgrowth in PC 12 cells and acts as an autophagy in MCF-7 cells. It has been reported that MG-132-induced autophagy is related to endoplasmic reticulum (ER) stress.

Applications

• 26S proteasome inhibitor

• Calpain inhibitor

• Anticancer reagent

References

• “Potential of the proteasomal inhibitor MG-132 as an anticancer agent, alone and in combination.”

• “Induction of autophagy by the MG‑132 proteasome inhibitor is associated with endoplasmic reticulum stress in MCF‑7 cells”

• “Inhibition of TNF- α -induced NF- κ B Activation and IL-8 Release in A549 Cells with the Proteasome Inhibitor MG-132”

Not for human therapeutic use or for medicinal purposes. For research applications only.